Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHA:605033)

SHA:605033 Revenue

Shaanxi Meibang Pharmaceutical Group had revenue of 144.92M CNY in the quarter ending September 30, 2026, with 17.29% growth. This brings the company's total for the last twelve months to 1.00B, up 15.06% year-over-year. In the year 2025, Shaanxi Meibang Pharmaceutical Group had annual revenue of 911.95M with 2.98% growth. That makes Shaanxi Meibang Pharmaceutical Group the 19,598th largest company in the world by revenue and 3,597th in China.

• Revenue (ttm): 1.00B
• Revenue Growth: +15.06%
• P/S Ratio: 2.28
• Revenue / Employee: 897.88K
• Employees: 1,117
• Market Cap: 2.28B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Fungicide 539.64M 59.4%
• Insecticides 261.94M 28.8%
• Others 107.25M 11.8%

By Geography

Chart

• China 907.66M 99.9%
• Overseas 1.18M 0.1%

Fiscal year ended Dec 31, 2025 See the full SHA:605033 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	911.95M	26.42M	2.98%
Dec 31, 2024	885.53M	186.50M	26.68%
Dec 31, 2023	699.03M	-207.02M	-22.85%
Dec 31, 2022	906.05M	63.56M	7.54%
Dec 31, 2021	842.49M	273.97M	48.19%

Data Source: S&P Global Market Intelligence Last updated: Oct 21, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 7, 2026

Data Sources Report a data error